Jazz Pharmaceuticals (JAZZ) Change in Accured Expenses (2010 - 2026)

Jazz Pharmaceuticals' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at $12.2 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 320.69% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was $37.3 million, a 152.52% increase from a year earlier, with the FY2025 full-year figure at $28.0 million, up 171.34% from the prior year.
• Change in Accured Expenses advanced to $12.2 million in Q1 2026 per JAZZ's latest filing, from -$22.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $148.1 million in Q4 2022 and bottomed at -$97.0 million in Q1 2023.
• The 5-year median for Change in Accured Expenses is $7.2 million (2023), against an average of $8.5 million.
• Across the five-year window, Change in Accured Expenses sank 507.87% in 2024 and surged 320.69% in 2026, its largest moves.
• Year by year, Change in Accured Expenses stood at $148.1 million in 2022, then plunged by 64.21% to $53.0 million in 2023, then sank by 280.51% to -$95.7 million in 2024, then jumped by 76.06% to -$22.9 million in 2025, then soared by 153.26% to $12.2 million in 2026.
• Per Business Quant, the three latest JAZZ Change in Accured Expenses figures stand at $12.2 million (Q1 2026), -$22.9 million (Q4 2025), and $126.3 million (Q3 2025).